Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.exelixis.com
Exelixis, Inc. News Releases
Get the latest updates from Exelixis, Inc. News Releases directly as they happen.
Follow now 105 followers
Latest posts
Last updated 4 days ago
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
4 months ago
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May...
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
4 months ago
– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s...
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
4 months ago
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
4 months ago
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May...
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
4 months ago
– CABOMETYX significantly reduced the risk of disease progression or death by...
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
3 months ago
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 22, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced...
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
about 2 months ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
about 1 month ago
- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues...
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
12 days ago
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
11 days ago
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Sep...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
7 months ago
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--Feb...
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
7 months ago
– Total Revenues of $599 million for the Fourth Quarter of 2025...